A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

NCT06913218 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreas Cancer
Pancreas Cancer, Duct Cell Adenocarcinoma

Interventions

BIOLOGICAL: AK154
BIOLOGICAL: Cadonilimab
BIOLOGICAL: Ivonescimab (SMT112 or AK112) Injection
DRUG: mFOLFORINOX

Sponsor

Akeso

Collaborators

[object Object]